论文部分内容阅读
目的对比长春新碱、阿霉素以及地塞米松(VAD方案)和硼替佐米、地塞米松以及环磷酰胺(PCD方案)治疗多发性骨髓瘤的临床疗效。方法 35例多发性骨髓瘤患者,随机分为对照组(19例)和观察组(16例),对照组采用VAD方案治疗,观察组采用PCD方案治疗,治疗后观察比较两组患者治疗效果。结果观察组有效率高于对照组,差异具有统计学意义(P<0.05);治疗后观察组患者骨髓瘤细胞、血红蛋白、M蛋白和β2-微球蛋白等各项临床指标改善情况与对照组相比,差异均具有统计学意义(P<0.05)。结论采用PCD方案治疗多发性骨髓瘤,可提高治疗有效率,进一步改善各项临床指标,值得临床推广。
Objective To compare the clinical efficacy of vincristine, doxorubicin and dexamethasone (VAD) and bortezomib, dexamethasone and cyclophosphamide (PCD) in the treatment of multiple myeloma. Methods Thirty-five patients with multiple myeloma were randomly divided into control group (n = 19) and observation group (n = 16). The control group was treated with VAD regimen and the observation group with PCD regimen. After treatment, the therapeutic effect was compared between the two groups. Results The effective rate of the observation group was higher than that of the control group (P <0.05). After treatment, the improvement of various clinical indexes such as myeloma cells, hemoglobin, M protein and β2-microglobulin in the observation group was not significantly different from that in the control group Compared with the difference was statistically significant (P <0.05). Conclusion PCD treatment of multiple myeloma, can improve the treatment efficiency, to further improve the clinical indicators, is worthy of clinical promotion.